SCHEMBL22078072

SCHEMBL22078072

Cn1c2ccc(-n3ccnc3)cc2c2ccc(C(=O)O)cc21

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADH5 P11766 11/20 0.53
KDM4E B2RXH2 1/20 0.51
TBXAS1 P24557 1/20 0.49
CYP3A4 P08684 1/20 0.49
BAZ2B Q9UIF8 1/20 0.49
HTT P42858 2/20 0.46
CYP4Z1 Q86W10 1/20 0.46
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22078064 0.83 ADH5 (0.53) ADH5KDM4ETBXAS1CYP3A4BAZ2B
SCHEMBL30772942 0.82 ADH5 (0.49) ADH5CYP3A4BAZ2BHTTCYP4Z1
SCHEMBL20535801 0.82 ADH5 (0.49) ADH5CYP3A4BAZ2BHTTCYP4Z1
SCHEMBL30927852 0.82 ADH5 (0.49) ADH5CYP3A4BAZ2BHTTCYP4Z1
SCHEMBL20536337 0.82 ADH5 (0.46) ADH5KDM4ETBXAS1CYP3A4BAZ2B
SCHEMBL30772967 0.82 ADH5 (0.46) ADH5KDM4ETBXAS1CYP3A4BAZ2B
SCHEMBL22078080 0.81 ADH5 (0.46) ADH5TBXAS1CYP3A4BAZ2BHTT
SCHEMBL22078076 0.81 TBXAS1 (0.53) ADH5KDM4ETBXAS1CYP3A4BAZ2B
SCHEMBL22077255 0.81 ESR1 (0.48) ADH5KDM4ETBXAS1CYP3A4BAZ2B
SCHEMBL22078070 0.80 TBXAS1 (0.46) KDM4ETBXAS1CYP3A4HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS, INC. 2020-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655244-B2 Carbazole compounds and methods of use thereof GSR, CBR3, CBR1 ADH5 93/4885KDM4E 3228/4885TBXAS1 1031/4885
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSR, CBR3, CBR1 ADH5 93/4885KDM4E 3228/4885TBXAS1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.